Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
Pseudomonas aeruginosa is one of the major causative microorganisms of ventilator-associated
pneumonia often resistant to antibiotics. In experimental models, nebulization of antibiotics
delivers high lung tissue concentrations of antibiotics in infected lungs and increases lung
bacterial killing. The aim of the study is to assess the efficiency of nebulized ceftazidime
and amikacin in the treatment of pneumonia caused by Pseudomonas aeruginosa in ventilated
patients.